Currently out of the existing stock ratings of Zarak Khurshid, 5 are a BUY (45.45%), 1 are a SELL (9.09%), 5 are a HOLD (45.45%).

Zarak Khurshid

Work Performance Price Targets & Ratings Chart

Analyst Zarak Khurshid, currently employed at WEDBUSH, carries an average stock price target met ratio of 100% that have a potential upside of 22.38% achieved within 443 days. Previously, Zarak Khurshid worked at JPMORGAN.

Zarak Khurshid’s has documented 22 price targets and ratings displayed on 4 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on CERS, Cerus at 17-Dec-2015.

Wall Street Analyst Zarak Khurshid

Analyst best performing recommendations are on EXAS (EXACT SCIENCES).
The best stock recommendation documented was for EXAS (EXACT SCIENCES) at 5/30/2014. The price target of $14 was fulfilled within 5 days with a profit of $0.52 (3.86%) receiving and performance score of 7.72.

Average potential price target upside

EXAS EXACT Sciences CERS Cerus RVTY Revvity ILMN Illumina

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold Since 24-Mar-2026

$85

7 months ago
(24-Mar-2026)

51/51 (100%)

$15.41 (22.14%)

294

Buy Since 10-Apr-2025

$105

$-1714.87 (-94.23%)

$85

9 months 4 days ago
(20-Jan-2026)

3/3 (100%)

$2.65 (2.59%)

89

Buy Since 03-Aug-2021

$105

$-1714.87 (-94.23%)

$68

9 months 19 days ago
(05-Jan-2026)

10/10 (100%)

$3.39 (3.34%)

392

Buy Since 09-Jul-2021

$105

$-1714.87 (-94.23%)

$75

10 months 29 days ago
(25-Nov-2025)

16/16 (100%)

$3.87 (3.83%)

607

Buy Since 06-Nov-2024

$80

11 months ago
(24-Nov-2025)

2/2 (100%)

$32.58 (68.71%)

229

Show more analysts

Please expand the browser size to see the chart

What Year was the first public recommendation made by Zarak Khurshid?

On 2012
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?